Introduction
Although gonorrhoea is a common sexually transmitted infection (STI), normally responsible for uncomplicated genital infections, the disease can sometimes lead to severe complications (salpingitis, epididymoorchitis, septicaemia) [1, 2] . It also increases the risk of transmission by human immunodeficiency virus (HIV) [2] . Because of its short incubation time (mainly 2 to 5 days) [3] and characteristic symptoms in men, the incidence of gonorrhoea can be used as a very sensitive indicator of the relaxation of safe sexual behaviours, and as an early warning signal for increased risk of HIV transmission [2] .
Following acquired immunodeficiency syndrome (AIDS) prevention campaigns in the 1980s and at the beginning of the 1990s, the number of cases of gonorrhoea in certain European Union (EU) and European Free Trade Association (EFTA) countries [4] , including France [5] , dropped significantly. This drop was the result of a reduction of at-risk sexual behaviours [6] . The advent of antiretroviral multitherapy in the mid-1990s brought with it a resurgence of these behaviours in the general population, especially in men who have sex with men (MSM). It also led to a resurgence in cases of gonorrhoea in some EU/EFTA countries [5, 6] as well as in the United States [7] .
In France, the epidemiological surveillance of gonorrhoea is based on two voluntary sentinel networks relying on clinicians (the RésIST network) or public and private laboratories (the Rénago network -National Gonorrhoea Network -) [8, 9] . Since the beginning of the 2000s, an increase in gonococcal infections has been observed by these networks, both in men and women [9] . The RésIST network also highlighted that this increase exists irrespective of sexual orientation [8, 9] .
At the end of the 1990s and the beginning of the 2000s, concomitantly with the resurgence of gonoccocal infections, several countries reported increasing levels of gonococcal resistance to ciprofloxacin [2, 10] , a fluoroquinolone antibiotic, which was used at the time as a single-dose first-line treatment for uncomplicated urogenital gonorrhoea. Since the mid-2000s, singledose third generation cephalosporins (TGC), specifically oral cefixime and injectable ceftriaxone, became the only remaining recommendable antimicrobial class [11] . These treatments were officially recommended in France at the end of 2005 [12] . However, the subsequent development of clinical and biological resistance to TGC, especially to cefixime, and, since the end of the 2000s, to ceftriaxone, may lead to a therapeutic dead end in the coming years [2, 11] . Surveillance of gonococcal susceptibility to these antibiotics is therefore essential.
Given this worrying context, the objective of this study was to describe the evolution of gonococcal infections and the changes in the susceptibility of gonorrhoea strains to antibiotics in France between 2001 and 2012. Factors associated with decreased susceptibility to TGC are also assessed.
Methods
The laboratories in the Rénago network are distributed throughout all of metropolitan France. This network helps monitor the resistance of Neisseria gonorrhoeae strains to antibiotics. Laboratory participation to surveillance is voluntary.
The laboratories receive patients referred by their doctor who prescribed a microbiological diagnosis for gonorrhoea. An anonymous epidemiological file, collected by the network laboratory microbiologist, provided the following information for each patient: sex, age, date of sample, anatomical site of sample, presence of symptoms, co-infection with another STI, probable country of infection, information on partner's infection, the place of consultation and specialisation of treating physician, type of laboratory and geographical area to which it belongs. The sexual orientation of the patient is not reported. Information is consolidated and analysed by the Institut de Veille Sanitaire (InVS). Because of the large proportion of missing data for four variables (presence of symptoms, co-infection with another STI, probable country of infection, and information on patient's partner infection status), the latter were used only for univariate analysis for descriptive purposes. All other variables were included in the multivariate analysis; p<0.05 was used as the level for significance. Only the results of multivariate analysis are presented here, unadjusted and adjusted odds-ratios being very similar. For the analyses, the data concerning the years from 2001 to 2009 were pooled to highlight recent developments of the characteristics of gonococcal infections and of antibiotic susceptibility of strains in the period from 2010 to 2012.
Gonococcal infection is laboratory confirmed by a positive culture or a positive nucleic-acid amplification test (NAAT) for N. gonorrhoeae by the network laboratories. Strains isolated by culture by the network laboratories are sent for antibiotic susceptibility testing to the Alfred Fournier Institute in Paris, which is the national reference laboratory (NRL) for gonorrhoea.
Because of the very high number of strains received by the NRL as well as budget constraints, the InVS and the NRL decided to separate epidemiological and microbiological surveillance. Although the epidemiological data collection continued for all laboratories in the network, the number of laboratories sending their strains to the NRL was reduced by about fifty per cent from the beginning of January 2012 (in 2012, 63 of the 133 laboratories in the network participated to the microbiological surveillance). Nevertheless, a homogeneous geographical distribution of laboratories continuing this microbiological surveillance was ensured ( Figure 1 ).
The NLR determines the minimum inhibitory concentration (MIC) for six antibiotics (penicillin G, tetracycline, ciprofloxacin, spectinomycin, ceftriaxone, and, since 2008, cefixime) using Etest strips (first from AB Biodisk, Solna, Sweden; then from AES Laboratory, Combourg, France, and from May 2011 from i2a, Pérols, France). These antibiotics were or are still recommended for the treatment of gonorrhoea [11] . The presence of beta-lactamases is detected using Api NH (bioMérieux, Marcy-l'Etoile, France) identification test kits and, when there is any doubt, using a chromogenic cephalosporin test (cefinase, bioMérieux). The criteria used to define resistance are those used by the European Committee on Antimicrobial Susceptibility Testing -EUCAST 2013 [13] . For TGC, no defined threshold exists for resistance; strains with a MIC>0.125 mg/L for cefixime and for ceftriaxone are regarded as having a decreased susceptibility. A strain was considered multi-resistant if it was resistant to penicillin G, tetracycline and ciprofloxacin, and if the MIC for cefixime or for ceftriaxone was >0.125 mg/L.
The factors associated with a reduction in susceptibility of gonorrhoea to TGC in patients aged at least 15 years-old were determined through univariate and multivariate analyses using Stata v.11.0 software, excluding missing values. As the number of strains with MIC>0.125 mg/L for TGC was low, we studied the factors associated with a MIC≥0.094 mg/L for cefixime and a MIC≥0.032 mg/L for ceftriaxone. These values were chosen arbitrarily to have a sufficient number of strains with MICs above these cut-offs to allow comparison analyses. Taking into account such cut-offs, 6% of strains had decreased susceptibility to these two antibiotics.
Results

Evolution of the number of gonococcal infections and analysed strains
Between 2001 and 2012, 13,400 cases of gonorrhoea were reported by the network's laboratories. From these cases, a total of 10,501 strains were sent to the NLR. The NLR succeeded in recultivating 8,649 (82%) of them to determine the susceptibility of N. gonorrhoeae to antibiotics. The proportion of strains sent to the NLR and then recultivated remained quite stable from 2005 to 2012 (84% on average for this period, range 82 to 87%). Number of participating laboratories (11) 180 (10) 228 (10) 254 (9) 1,350 (10) Not provided 228 (4) 43 (2) 57 (3) 62 (2) (12) 278 (15) 459 (21) 839 (28) 2,321 (17) Anus 588 (9) 98 (5) 105 (5) 77 (3) 868 (6) Pharynx 35 (1) 8 (<1) 23 (1) 33 (1) 99 (1) Other sites 112 (2) 24 (1) 25 (1) 35 (1) 196 (1 (10) 156 (9) 262 (12) 386 (13) 1,438 (11) Dermatologist-venereologist 860 (13) 100 (6) 86 (4) 168 (6) 1,214 (9) Other medical specialisation 877 (14) 256 (14) 320 (14) 381 (13) 
Epidemiological and clinical characteristics of cases of gonorrhoea
The clinical characteristics of reported cases of gonorrhoea are shown in Table 1 In men, samples were taken mainly from the urethra or urine (90%: 9,741/10,820). Samples from the anus 
Evolution of the susceptibility of gonococcal strains to antibiotics
The analysis is based on 8,649 gonococcal strains tested by the NLR. Proportionally, more strains were tested from men (70%: 7,569/10,815) than women (42%: 1,070/2,564; p<0.001). Furthermore anal samples were tested proportionally more often (84%: 730/868) than samples from the other anatomical sites (63%: 7,898/12,478; p<0.001). The proportion of strains with decreased susceptibility to cefixime (MIC>0.125 mg/L) was less than 1% until 2011 (Table 2 Restricted analysis of those laboratories which reported throughout the whole study period and continued to participate in microbiological surveillance during 2012 provided similar results in terms of the evolution of the susceptibility of gonococcal strains to antibiotics between 2001 and 2012 (data not shown).
Factors associated with a reduction in the susceptibility of gonococcal strains to third generation cephalosporins in patients 15 years and older Univariate analysis was performed using the variables from Table 1 . The proportion of strains with decreased susceptibility to cefixime (MIC≥0.094 mg/L) and to ceftriaxone (MIC≥0.032 mg/L) ( Table 3 ) was significantly associated with age group, year of surveillance and For each variable, the number of strains with decreased susceptibility (n) is given relative to the total tested for the antibiotic (N) as well as the percentage. The multivariate analysis includes all the variables in the geographical area. This proportion was also greater in the absence of gonorrhoea-associated STI, notably in the absence of co-infection with chlamydia. Furthermore the proportion of strains with decreased susceptibility to cefixime was associated with anatomical site of sample, presence of symptoms and place of consultation.
Multivariate analysis (Table 3) was performed using the variables from Table 1 excluding four variables with a large proportion of missing data (as mentioned in the methods section). The proportion of strains with decreased susceptibility to cefixime (MIC≥0.094 mg/L) increased in the 2010 to 2012 period. Indeed, this proportion was 2.7 times greater in 2012 than for the period between 2001 and 2009. This reduced susceptibility increased with the patients' age. It was almost four times higher for strains derived from the pharynx than for those derived from the urethra, even when analysis was restricted to male patients (adjusted odds ratio 4.2; 95% CI: 1.5-11.6; p=0.006). Finally, the decrease in susceptibility to cefixime was found to be higher in the north-eastern area of France.
The proportion of strains with decreased susceptibility to ceftriaxone increased in the 2010 to 2012 period, this increase being particularly sharp in 2010. Taking 2010 as the reference year, the proportion of strains with decreased susceptibility to ceftriaxone (MIC≥0.032 mg/L) significantly diminished in the 2011 to 2012 period. As was the case for cefixime, decreased susceptibility for ceftriaxone increased with patients' age, was higher for pharyngeal-based strains (even when restricting the analysis to male patients) (adjusted odds ratio: 3.4; 95% CI: 1.4-8.2; p=0.008) and was higher in the north-eastern area of France.
Multivariate analysis of the 2001 to 2012 period, restricted to the laboratories which continued microbiological surveillance in 2012, provided similar results (data not shown).
Discussion
The microbiological surveillance network in France shows that the proportion of resistant strains to antibiotics fluctuated around 13% for penicillin G over the whole study period. It increased throughout the study for tetracycline, reaching 56% in 2012. For ciprofloxacin it increased between 2003 and 2006 after which it remained high at around 42%. These three families of antibiotics have a resistance level which prevents them from being used in current practice for the treatment of gonorrhoea. Indeed, according to the World Health Organization, first-line treatment must cure at least 95% of patients and must not be used if more than 5% of strains are resistant [2] .
Gonorrhoea was susceptible to spectinomycin throughout the study period. The marketing of this antibiotic in France stopped in 2008 and then started again since 2011. However, therapeutic failures for pharyngeal-based infections have led it to become a second-line treatment when there are contraindications to beta-lactam antibiotics [15] .
The proportion of strains with decreased susceptibility to cefixime (MIC>0.125 mg/L) remained moderate, less than 5%, but it quadrupled between 2011 and 2012. Furthermore, the proportion of isolates with high MIC values (MIC≥0.094 mg/L) increased consistently in recent years ( Figure 4 and Table 3 ). The only two strains presenting MICs>0.125 mg/L to ceftriaxone were both detected in France in 2010, and one of these was associated with therapeutic failure using cefixime in an infected patient [14] . With respect to ceftriaxone, the number or proportion of isolates with high MIC values (MIC≥0.032 mg/L) did not increase in 2011 or 2012.
The very rare cases of decreased susceptibility to ceftriaxone [14, [16] [17] [18] [19] and cases of therapeutic failure with cefixime described in Japan, Canada and Europe [14, [20] [21] [22] [23] , confirm the recommendations made by the French Agency for Medicine published in 2005 [12] , which were reaffirmed in 2008 [15] . These guidelines recommend the use of ceftriaxone (500 mg singledose injection) in first-line treatment, and that the use of cefixime (400 mg single-dose oral) be reserved for cases of patient refusal or when parenteral treatment is not possible.
Nevertheless, the increase in gonococcal decreased susceptibility to cefixime observed in France suggests that clinicians may have continued to prescribe this antibiotic as a first-line treatment after the recommendations of 2005 were published (and reaffirmed in 2008). Indeed, a study performed in 2008 on general practitioners in the 'Sentinelles' network showed that only a minority of prescribing doctors were aware of the 2005 recommendation to abandon ciprofloxacin in favour of TGC [24] . By analogy, it is possible that in 2012 doctors had not yet sufficiently implemented the recommendation reiterated in 2008 regarding the use of TGCs [15] . A new study on doctors' prescriptions could help support this hypothesis. Another hypothesis to explain the recent increase in gonococcal resistance to cefixime is the spread of a resistant clone [25] .
The levels of resistance to penicillin G, tetracycline and ciprofloxacin in France were higher than those found in the United States, but of the same order for TGC and multidrug resistance [26] . In contrast, the levels of resistance in France were of the same order as European levels for penicillin G and ciprofloxacin, but lower for TGC [27] .
We currently do not have data on the susceptibility of gonorrhoea to azithromycin. In France this antibiotic is taken in a single, 1 g dose with ceftriaxone in suspected cases of urethritis and cervicitis [12, 15] . Elsewhere, notably in the United States, azithromycin is recommended in monotherapy for gonococcal infections, in the case of allergies to TGC [28] . Because of resistance to azithromycin described in various countries [26, 29] this antibiotic is being tested within the Rénago network as of 2013.
Our study shows factors associated with a reduction in the susceptibility to TGC. We acknowledge that the combination of data from 2001 to 2009 only allowed to highlight the recent epidemiological and microbiological changes. The proportion of strains with decreased susceptibility to TGC increased with patients' age. This has already been observed for other antibiotics (penicillin and tetracycline) in Canada [29] . A lower proportion of gonococcal resistant strains in the case of co-infection with chlamydia was found for cefixime in the United Kingdom [30] and for ciprofloxacin at the European level [27] , although the reason for this is not clearly established.
The proportion of strains with decreased susceptibility to TGC did not differ significantly according to sex. Anal-based strains did not present higher decreases in susceptibility than urethral-based strains. However, the proportion of pharyngeal-based strains with decreased susceptibility to TGC was three to four times higher than urethral-based strains. This may be explained by the horizontal transfer of gene mutations associated with decreased susceptibility to TGC from oral commensal Neisseria [31] . Anal and pharyngeal gonorrhoea in men was probably acquired through homosexual transmission, although the absence of information on sexual behaviours from the Rénago network prevents us from being certain about this. Several studies have shown that MSM are likely to be infected more frequently and more quickly than heterosexuals by resistant gonococcal strains [26, 30, 32] . This fact highlights the need for specific surveillance of antibiotic susceptibility in MSM. We found that the monitoring of anal strains brought information on resistance similar to those of urethral strains. Despite the absence of behavioural data, our study shows, however, that increased monitoring of pharyngealbased strains with respect to decreased susceptibility to TGC seems essential.
Finally, we observed a higher level of decreased susceptibility in the north-eastern area of France. It is hard to interpret the reason for this. Obviously this area should remain under close scrutiny, while still keeping the national distribution of the network's laboratories homogeneous.
In the Rénago network, an increase in the number of declared gonococcal infections occurred over the 2001 to 2012 period. Several interlinked phenomena contributed to this: the real growth in infections, the increase in NAAT diagnoses, the increase in the number of participating laboratories and the growing shift towards the consolidation of laboratories. Despite this complex evolution, the Rénago network continued to help monitor gonococcal resistance to antibiotics. This microbiological surveillance network would appear to be reliable as the changes that have been made to it have (the reduction by half of the number of laboratories submitting strains to the NRL), a priori, had little or no effect on the proportion of resistant strains observed. Restricted analysis to those laboratories which continued to participate in microbiological surveillance in 2012 provides strong evidence for this. The emergence of resistance to TGC is extremely worrying as the latter represent the last line of treatment, with no therapeutic alternatives currently available [31] . This fact justifies the continuation of microbiological surveillance of gonorrhoea at a collective level in order to adjust therapeutic recommendations. Meanwhile, surveillance of therapeutic failure with respect to TGC is currently being implemented at the European level [33] . Given the increase in NAAT diagnosis, it is essential that medical laboratories continue to perform gonococcal cultures which adapt care to the individual's needs while waiting for molecular tests on susceptibility to antibiotics to be developed and made accessible [2] .
